Service GLP-1 Medication Platform Offering Affordable Access to Semaglutide, Tirzepatide, and Phentermine with 24/7 Coaching, ...

From ‘Ozempic face’ to ‘Ozempic fingers’ and even ‘Wegovy butt,’ the potential side effects of weight loss medications have ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...